ABOUT US

Our Story At PawThNeo, our journey didn’t begin in a laboratory; it began with Goldie.

Five years ago, Goldie, a resilient rescued Labrador, was diagnosed with osteoarthritis. Like many pet parents, we navigated endless veterinary visits and tried everything available, including a multitude of supplements and non-steroidal anti-inflammatory drugs (NSAIDs) during acute flare-ups. Yet, despite our best efforts, we watched as the condition steadily affected all of her limbs. The existing treatments didn't offer a cure; they merely offered symptom management, often accompanied by the heavy burden of side effects.

We quickly realized that this heartbreaking reality extends beyond our canine companions. For humans with osteoarthritis, the medical landscape is much the same: a reliance on medications that manage pain but fail to halt the disease, often complicating life for individuals with comorbidities.

Goldie’s struggle exposed a critical gap in how we treat joint health and mobility loss. PawThNeo was founded by Dr Anirudha Lakshminarasimhan to bridge that gap. As a forward-thinking biopharmaceutical initiative, we are driven by the urgent need to move beyond mere symptom management. Our focus is on developing innovative, science-backed therapeutic solutions that aim to address the root causes of degenerative conditions without the cascading side effects of traditional medications.

We remain forever indebted to Goldie. She continues to be the silent, guiding support behind this initiative—inspiring us every day to push the boundaries of biotechnology and create a world where growing older doesn't have to mean slowing down.